On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population

Nordic Journal of Psychiatry

Volumn 61, Issue 2, 2007, Pages 152-157

  Markkula, Juha ^a   Helenius, Hans ^b   Lauerma, Hannu ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Mental Hospital for Prisoners   (Finland)

Author keywords

Akathisia; Antipsychotics; Prevalence

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERPHENAZINE DECANOATE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PSYCHOSIS; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 34247095585     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039480701226146     Document Type: Article

References (21)

1. Van Putten, T. (1974) Why do schizophrenic patients refuse to take their drugs?. Arch Gen Psychiatry, 31, pp. 67-72.
2. Van Putten, T. (1975) The many faces of akathisia. Compr Psychiatry, 6, pp. 43-47.
3. Drake, RE and Erlich, J. (1985) Suicide attempts associated with akathisia. Am J Psychiatry, 142, pp. 499-501.
4. Shear, MK, Frances, AK and Weiden, P. (1983) Suicide associated with akathisia and depot fluphenazine treatment. Suicide, 3, pp. 235-236.
5. Atbaoglu, E Cem, Schultz, SK and Andreasen, NC. (2001) The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci, 13, pp. 336-341.
6. Sachdev, P. (1994) Research diagnostic criteria for drug-induced akathisia: Conceptualization, rationale and proposal. Psychopharmacology, 114, pp. 181-186.
7. Geddes, J., Freemantle, N., Harrison, P. and Bebbington, P. (2000) Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. Br Med J, 321, pp. 1371-1376.
8. Melkersson, K. and Dahl, ML. (2004) Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications. Drugs, 64, pp. 701-723.
9. Hofer, A., Hummer, M., Huber, R., Kurz, M., Walch, T. and Fleischhacker, WW. (2000) Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol, 20, pp. 699-702.
10. Lipinski, JF, Gopinath, M., Zimmermann, P. and Pope, HG. (1989) Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry, 50, pp. 339-342.
11. Bazire, S. (2003) Psychotropic drug directory/04, Fivepin Publishing, Salisbury, Wilts
12. Woods, SW. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry, 64, pp. 663-667.
13. Barnes, TRE. (1989) A rating scale for drug-induced akathisia. Br J Psychiatry, 154, pp. 672-676.
14. Sachdev, P. (1995) The epidemiology of drug-induced akathisia: Part 1. Acute akathisia. Schizophr Bull, 21, pp. 431-449.
15. Janno, S., Holi, M., Tuisku, K. and Wahlbeck, K. (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry, 161, pp. 160-163.
16. Syvälahti, EK, Taiminen, T., Saarijarvi, S., Lehto, H., Niemi, H., Ahola, V., Dahl, ML and Salokangas, RK. (1997) Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res, 25, pp. 24-32.
17. Lee, MS, Kim, YK, Lee, SK and Suh, KY. (1998) A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol, 18, pp. 399-403.
18. Tuisku, K., Lauerma, H., Holi, M., Markkula, J. and Rimon, R. (1999) Measuring neuroleptic-induced akathisia by three-channel actometry. Schizophr Res, 40, pp. 105-110.
19. Leucht, S., Wahlbeck, K., Hamann, J. and Kissling, W. (2003) New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet, 361, pp. 15581-15589.
20. Poyurovsky, M., Shardorodsky, M., Fuchs, C., Schneidman, M. and Weizman, A. (1999) Treatment of neuroleptic-induced akathisia with the 5HT2 antagonist mianserin. Double blind, placebo-controlled study. Br J Psychiatry, 174, pp. 238-242.
21. Poyurovsky, M., Epshtein, S., Fuchs, C., Schneidman, M., Weizman, R. and Weizman, A. (2003) Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: A double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol, 23, pp. 305-308.